Current Approach for Treating Anemia in LR-MDS
A medical oncologist outlines approaches to treating anemia in patients with lower-risk myelodysplastic syndromes.
Video content above is prompted by the following:
- What is your current approach for treating anemia in LR-MDS?
- When would you choose ESAs for first-line treatment?
- When would you switch therapies? Would you dose escalate before switching to an EMA (e.g. second-line)?
- What factors lead to a decision to use luspatercept as a first-line treatment?
- When do you dose escalate?
- When do you dose escalate?
- When would you choose ESAs for first-line treatment?
Recent Videos
Related Content
COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS
October 23rd 2024Article
During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
Read More
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024Article
During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
